Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Research Area
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

FQI 1 is an inhibitor of Late SV40 Factor (LSF) transactivation activity (IC50 = 2.1 µM).1 It inhibits growth of NIH3T3, HeLa S3, and A549 cancer cells (GI50s = 3.8, 0.79, and 6.3 µM, respectively). FQI 1 decreases viability of QGY-7703 and Huh7 liver cancer cells, but not of non-cancerous Hc3716-hTERT cells and primary mouse hepatocytes, when used at a concentration of 4 µM.1,2 It reduces tumor growth induced by N-nitrosodiethylamine (DEN) in mice and in a QGY-7703 hepatocellular carcinoma (HCC) mouse xenograft model when administered at doses of 4 and 1 mg/kg, respectively.
WARNING This product is not for human or veterinary use.
1. Antiproliferative small-
2. Small molecule inhibitors of Late SV40 Factor (LSF) abrogate hepatocellular carcinoma (HCC): Evaluation using an endogenous HCC model. Oncotarget 6(28), 26266-26277 (2015).